scholarly journals THE USE OF KETOPROFEN NIOSOMES FOR FORMULATION OF SUSTAINED RELEASE TABLET DOSAGE FORM

2012 ◽  
Vol 46 (2) ◽  
pp. 90-99
Author(s):  
Mohamed Raslan
Keyword(s):  
Sustained Release ◽  
Dosage Form ◽  
Sustained Release Tablet ◽  
Tablet Dosage ◽  
Release Tablet

Sustained release tablet formulation of diethylcarbamazine. Part II

1985 ◽  
Vol 24 (2-3) ◽  
pp. 355-358 ◽  
Author(s):  
S.K. Baveja ◽  
K.V. Ranga Rao ◽  
Rajinder Kumar ◽  
K. Padmalatha Devi
Keyword(s):  
Sustained Release ◽  
Tablet Formulation ◽  
Sustained Release Tablet ◽  
Release Tablet

DESIGN DEVELOPMENT AND OPTIMIZATION OF A SUSTAINED RELEASE TABLET OF BOSENTAN MONOHYDRATE FOR PULMONARY ARTERIAL HYPERTENSION

INDIAN DRUGS ◽  
2019 ◽  
Vol 56 (03) ◽  
pp. 61-67
Author(s):  
P. P Dighe ◽  
H. M Tank ◽  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Sustained Release ◽  
Arterial Hypertension ◽  
In Vitro Release ◽  
Design Development ◽  
23 Factorial Design ◽  
Sustained Release Tablet ◽  
Pulmonary Arterial ◽  
Release Tablet

Pulmonary arterial hypertension (PAH) means high blood pressure in the lungs caused by obstruction in the small arteries of the lungs.The current study involves the fabrication of oral matrix sustained release tablet of bosentan monohydrate, a dual endothelin receptor antagonist, the optimisation of its in vitro release and characterisation. Methocel K4M PremiumDC2, a directly compressible HPMC grade, has been used as the sustained release polymer. Pregelatinised starch is used as a diluent and release modifier and sodium lauryl sulphate as a solubiliser. The influence of the above variables on drug release is measured using a 23 factorial design using design expert software. Surface response plots show significant interaction among the formulation variables, thus aiding in optimization of bilayer tablet.

scholarly journals Preparation and Evaluation of Nifedipine sustained release Tablet by using Natural Gums as release retardant

2014 ◽  
Vol 01 (03) ◽  
pp. 78-84 ◽  
Author(s):  
Gayatri D Medisetty ◽  
Girish B Botta ◽  
Uma maheshwari Yamana ◽  
Ashwini Avasarala
Keyword(s):  
Sustained Release ◽  
Sustained Release Tablet ◽  
Preparation And Evaluation ◽  
Release Tablet

Novel Chewable Sustained‐Release Tablet Containing Verapamil Hydrochloride

2004 ◽  
Vol 9 (2) ◽  
pp. 181-188 ◽  
Author(s):  
Omaima N. El‐Gazayerly ◽  
Vipaporn Rakkanka ◽  
James W. Ayres
Keyword(s):  
Sustained Release ◽  
Verapamil Hydrochloride ◽  
Sustained Release Tablet ◽  
Release Tablet

Pharmacokinetics of Pentoxifylline after Oral Administration of a Sustained Release Tablet at Two Different Times of the Day

2011 ◽  
Vol 49 (09) ◽  
pp. 750-753
Author(s):  
Poondru Srinivasu ◽  
Devraj Rambhau ◽  
Boinpally Rao ◽  
Yamsani Rao
Keyword(s):  
Sustained Release ◽  
Oral Administration ◽  
Sustained Release Tablet ◽  
Release Tablet

scholarly journals Optimized chronomodulated dual release bilayer tablets of fexofenadine and montelukast: quality by design, development, and in vitro evaluation

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Bhupendra Singh ◽  
Geetanjali Saini ◽  
Manish Vyas ◽  
Surajpal Verma ◽  
Sourav Thakur
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Quality By Design ◽  
Immediate Release ◽  
Oral Dosage ◽  
Nocturnal Asthma ◽  
Sustained Release Tablet ◽  
Bilayer Tablets ◽  
Dual Release ◽  
Release Tablet

Abstract Background The conventional oral dosage forms are not effective in dealing with chronopathological conditions, such as nocturnal asthma. Therefore, there is an unmet need to develop a delivery system that can deliver drug as per the chronopharmacology of the diseases. The purpose of the study is to use quality by design (QbD) technique and pulsatile principles for the development of Eudragit-coated dual release bilayer tablets. The dual layer consists of immediate release layer of fexofenadine HCl and sustained release layer of montelukast sodium. Results The quality target product profile of the formulation was developed, and the critical quality attributes were identified. Three-level, three-factor Box-Behnken design was used for the optimization of the bilayer tablets. Based on the design, a total of 13 formulation combinations (F1–F13 and M1–M13) were made having acceptable micromeritic properties. The developed immediate and sustained release layers were evaluated for physicochemical properties. Depending upon the value of the diffusion exponent, the Fickian diffusion mechanism is dominant among immediate and sustained release tablet layers. Response curve for immediate release layer showed that concentrations of sodium starch glycolate and sodium bicarbonate had a negative effect on disintegration time and a positive effect on drug release. For sustained release tablet layer, concentrations of HPMC E 5 LV and magnesium stearate had a significant effect on drug release. The ANOVA and diagnostic plots confirmed the significance and goodness of fit of the used model. Based on desirability plot values, optimized formulation was developed and coated with Eudragit coat. The coated bilayer tablet showed met the requirement of providing an immediate release during the first hour and a sustained release action for a period of more than 8 h after passing the gastric region. Conclusions The formulation can be fruitful in curbing the menace of nocturnal asthma and providing a high degree of patient compliance as the patient will not have to wake up at night to take the medication.

Sign in / Sign up

Export Citation Format

Share Document